Developer docs
API playgroundTry for free, no card

Search company profiles

Cristal Therapeutics

Full company profile

uuid0002l3u

Namestring
Cristal Therapeutics
Legal namestring
Cristal Therapeutics
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Cristal Therapeutics is a privately-held Dutch biotechnology company, founded in 2011 as a Utrecht University spin-off (originally Cristal Delivery B.V.) and headquartered in Maastricht, that builds and licenses three interconnected proprietary technology platforms: CliCr®, a copper-free click chemistry reagent based on TMTHSI that enables fast, site-specific bioconjugation without copper catalysis; CriPec®, a polymeric nanoparticle platform that transforms drug molecules into nanoparticles with negligible protein corona formation, enabling enhanced tumour accumulation and sustained drug release (clinically demonstrated at approximately 4-fold higher tumour uptake versus conventional docetaxel); and CriVac®, a vaccine platform that combines CriPec® nanoparticles with CliCr® conjugation to produce virus-mimicking coated nanoparticles that induce immune responses against displayed antigens. Its lead clinical asset, CPC634 (CriPec®-docetaxel), is in Phase 2 development for platinum-resistant ovarian cancer and other solid tumours, supported by a €2.5 million Horizon 2020 SME Instrument grant.

The company operates a licensing- and partnership-led business model rather than a commercial product sales model. Revenue is generated through technology licensing agreements (both exclusive and non-exclusive) for the CliCr®, CriPec®, and CriVac® platforms with pharmaceutical and biotech partners, supplemented by research and distribution arrangements. CliCr® reagents for non-GMP research are sold through Iris Biotech GmbH as authorized distributor; GMP applications and clinical-stage engagements are handled directly via the business development team. Strategic partners include Lonza (CliCr® embedded in its Bioconjugation Toolbox), Curapath (co-exclusive license for nucleic acid drug delivery), Sapreme Technologies (non-exclusive license), TBD Pharmatech (exclusive supply), Intravacc (COVID-19 vaccine collaboration), and iTeos Therapeutics (immuno-oncology). To date the company has raised over €20 million in equity financing from Thuja Capital, BioGeneration Ventures, Chemelot Ventures, Aglaia BioMedical Ventures, DROIA Oncology Ventures, and regional Dutch/Belgian funds, complemented by European Commission grants.

The company is small (1–10 employees) and is led by CEO/CMO Dr. Axel Mescheder (appointed November 2018, formerly of Pfizer, MSD, MediGene, and TopoTarget), Founder/CSO Dr. Cristianne Rijcken, CFO Andre Verwei (appointed 2019), CBO Jeroen Tonnaer, and Board Chairman Dr. Werner Cautreels (former CEO of Selecta Biosciences). The current strategic emphasis, evidenced by a cluster of 2023–2025 CliCr®-focused partnerships, has shifted from internal clinical development of CPC634 toward broader out-licensing of the CliCr® platform into bioconjugation, peptide synthesis, nucleic acid delivery, and gene-editing applications.

Short descriptiontext

Cristal Therapeutics is a Dutch clinical-stage biotech that develops and licenses three proprietary platforms — CliCr® copper-free click chemistry, CriPec® polymeric nanomedicines, and CriVac® vaccines — serving pharmaceutical and biotech partners developing cancer therapeutics, bioconjugates, and gene-editing delivery systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMaastricht, Netherlands
HQ citystring
Maastricht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanoparticle drug delivery, bioconjugation technology, copper-free click chemistry, pharmaceutical licensing services, clinical-stage nanomedicines
NAICS code3 codes
  • Research and Development in Nanotechnology541713
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
Product category
Nanomedicine Technology
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Cristal Therapeutics licenses its proprietary technology platforms (CliCr, CriPec, CriVac) to pharmaceutical and biotech partners under license agreements for various diagnostic and therapeutic applications. The company offers both exclusive and non-exclusive licensing arrangements.

cristaltherapeutics.com
2Research Grants
TypeLicensing Royalties
Description

The company has secured significant grant funding from European programs including Horizon 2020 SME Instrument grants (€2.5 million) and INNOSUP grants to support clinical development and platform advancement.

cristaltherapeutics.com
3Equity Financing
TypeLicensing Royalties
Description

Private company that has raised over €20M in equity financing from venture capital investors including Thuja Capital, BioGeneration Ventures, Aglaia BioMedical Ventures, DROIA Oncology Ventures, and others.

cristaltherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1CliCr®
Description

Proprietary copper-free click chemistry reagent technology platform enabling efficient, site-specific and stable conjugation of biomolecules for therapeutic and diagnostic applications.

cristaltherapeutics.com
+3 more records
Core offering1 text field

Cristal Therapeutics develops and licenses proprietary nanomedicine platforms for therapeutic and diagnostic applications. The company offers three interconnected technology platforms — CliCr® (copper-free click chemistry reagents), CriPec® (polymeric nanoparticle drug delivery), and CriVac® (vaccine technology) — licensed to pharmaceutical and biotech partners. Its lead clinical candidate CPC634 combines CriPec® nanoparticles with docetaxel and is in Phase 2 development for platinum-resistant ovarian cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4-fold higher tumour accumulation of CriPec-docetaxel compared to conventional Taxotere in clinical studies
+4 more records
Product overview1 text field

Cristal Therapeutics is a clinical-stage pharmaceutical company offering three interconnected proprietary technology platforms: CliCr® (copper-free click chemistry reagent), CriPec® (polymeric nanoparticle drug delivery platform), and CriVac® (vaccine technology platform). These platforms work together to improve therapeutic profiles through superior conjugation (CliCr®), enhanced target specificity (CriPec®), and selective immune responses (CriVac®). The lead product candidate CPC634 combines CriPec® nanoparticles with docetaxel for cancer treatment. The company licenses these technologies under various agreement types and also commercializes CliCr® reagents through distribution partners.

Product and service4 records
1CliCr® Copper-Free Click Chemistry Reagent
CategoryBioconjugation Technology
Description

Proprietary copper-free click chemistry reagent platform based on TMTHSI (tetramethyl tetrahydroisoquinoline) that enables site-specific, stable, and fast conjugation of small molecules, biologics, nanoparticles, and other moieties via strain-promoted azide-alkyne cycloaddition, licensed to partners for therapeutic and diagnostic applications.

2CriPec® Polymeric Nanoparticle Drug Delivery Platform
CategoryNanoparticle Drug Delivery
Description

Polymeric nanoparticle technology platform that transforms drug molecules into customized nanoparticles via self-assembly, providing enhanced tumor accumulation, negligible protein corona formation, sustained drug release at target sites, and improved therapeutic profiles for cancer and other diseases, licensed to pharmaceutical partners.

3CriVac® Vaccine Technology Platform
CategoryVaccine Technology
Description

Proprietary vaccine technology platform combining biodegradable CriPec® nanoparticles with CliCr® conjugation chemistry for fast and controlled antigen conjugation, generating virus-mimicking coated nanoparticles that induce potent immune responses safely against displayed antigens, applicable for vaccine development.

4CPC634 (CriPec®-Docetaxel)
CategoryClinical-Stage Pharmaceutical Product Candidate
Description

Lead clinical-stage nanomedicine candidate combining CriPec® nanoparticles with entrapped docetaxel (Taxotere®) for treatment of platinum-resistant ovarian cancer and solid tumors, designed to enable enhanced tumor accumulation and localized drug release.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-26
Description

Co-exclusive license agreement for CliCr bioconjugation platform. Curapath serves as exclusive CDMO to apply CliCr for delivery of nucleic acids via targeted polymeric and lipid nanoparticles (LNPs). Both parties have right to grant sublicenses in nucleic acid drug delivery field.

2TBD Pharmatech
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-09-23
Description

Exclusive supply agreement where TBD Pharmatech serves as sole supplier of CliR conjugation reagents. Partnership leverages TBD Pharmatech's GMP manufacturing expertise and quality assurance for reliable, scalable production of CliCr to support Cristal Therapeutics' initiatives.

cristaltherapeutics.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-11
Description

Non-exclusive license agreement allowing Sapreme Technologies to leverage CliCr platform in development of next-generation therapeutics based on their endosomal escape technology. Integration with CliCr enables accelerated pipeline development with robust manufacturing strategy.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-25
Description

Iris Biotech sells CliCr and CliCr reagents for non-GMP research purposes as authorized distributor. For GMP applications, customers connect directly with Cristal Therapeutics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-17
Description

Cristal Therapeutics collaborates with Lonza on CliCr technology. CliCr is offered as part of Lonza's Bioconjugation Toolbox and Early Development Service offering. Lonza supports the entire product lifecycle from drug discovery through commercial manufacturing. The collaboration extends the impact of CliCr for use in bioconjugation applications in therapeutic and diagnostic products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-06
Description

Strategic collaboration to develop novel vaccine programs against human diseases with initial focus on COVID-19. Cristal provides CliCr and CriVac technology; Intravacc provides OMV technology and detoxified LPS technology. First joint CriVac vaccine candidate targets receptor-binding domain of SARS-CoV-2.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-12-06
Description

Strategic partnership for development of immuno-oncology therapeutic candidates using CriPec nanotech platform. Initial goal to determine efficacy of iTeos immuno-oncology drug candidates in preclinical models. Option for iTeos to license Cristal's platform for up to three immune tumor-targeting programs.

8PX Biosolutions
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-07-14
Description

Collaboration focused on application of CriVac vaccine technology for design of innovative vaccines. PX Biosolutions' DCtag vaccine formulations combined with Cristal's CriVac technology for enhanced vaccine platform flexibility.

cristaltherapeutics.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing nanoparticle-based immunomodulatory therapies (ImmTOR, Treg therapies). Directly comparable as a nanoparticle platform company with both therapeutics and vaccine applications, overlapping with both CriPec and CriVac.

TypeDirect peer
Description

German biotech developing antibody-drug conjugates based on proprietary amanitin payload and linker chemistry. Directly comparable as a bioconjugation platform company with a similar licensing-focused business model overlapping with CliCr chemistry applications.

TypeDirect peer
Description

Swiss biotech (now part of Boehringer Ingelheim) that developed site-specific antibody-drug conjugates using enzymatic conjugation chemistry. Directly comparable to Cristal as a bioconjugation platform company targeting ADCs and related modalities.

TypeDirect peer
Description

Australian-listed biotech developing dendrimer-based nanoparticle drug delivery (DEP platform) with applications in oncology and infectious disease. Direct peer as a clinical-stage nanomedicine platform company with both internal products and licensing deals.

5NanoCarrier
TypeDirect peer
Description

Japanese clinical-stage biotech developing polymeric micelle nanoparticle drug delivery systems (e.g., NC-6004, NC-6300) for oncology. Direct peer in the polymeric nanoparticle drug delivery space, comparable in stage, mechanism, and oncology focus to CriPec.

6Vivesto (formerly Oasmia Pharmaceutical)
TypeDirect peer
Description

Swedish nanomedicine company developing proprietary nanoparticle formulations of chemotherapeutics (e.g., Apealea/paclitaxel). Direct peer as a nanoparticle reformulation company targeting oncology indications with improved tolerability profiles.

7CytImmune Sciences
TypeDirect peer
Description

Clinical-stage biotech developing tumor-targeted gold nanoparticle therapeutics (Aurimune, CYT-6091) combining delivery and immunotherapy. Direct peer in oncology-focused nanoparticle drug delivery and a comparable platform-based licensing model.

TypeDirect peer
Description

Clinical-stage biotech developing lipid nanoparticle (LNP)-enabled RNA medicines, including partnered COVID-19 and influenza vaccines. Directly comparable as an LNP delivery platform company with applications in both therapeutics and vaccines, overlapping with CriPec and CriVac.

TypeEmerging player
Description

Dutch preclinical biotech developing endosomal escape technology to enhance intracellular delivery of therapeutics (ADCs, oligonucleotides). Comparable as a recently-signed CliCr licensee and a delivery-technology peer adjacent to CliCr-enabled bioconjugation.

TypeEmerging player
Description

Spanish CDMO specializing in polymer and lipid-based drug delivery systems (LNPs, polymeric nanoparticles). Co-exclusive CliCr licensee for nucleic acid delivery via LNPs; comparable as an emerging delivery-tech peer adjacent to both CliCr and CriPec applications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cristal Therapeutics

Nanomedicine Technologycristaltherapeutics.com

Cristal Therapeutics is a Dutch clinical-stage biotech that develops and licenses three proprietary platforms — CliCr® copper-free click chemistry, CriPec® polymeric nanomedicines, and CriVac® vaccines — serving pharmaceutical and biotech partners developing cancer therapeutics, bioconjugates, and gene-editing delivery systems.

What Cristal Therapeutics does

Cristal Therapeutics is a privately-held Dutch biotechnology company, founded in 2011 as a Utrecht University spin-off (originally Cristal Delivery B.V.) and headquartered in Maastricht, that builds and licenses three interconnected proprietary technology platforms: CliCr®, a copper-free click chemistry reagent based on TMTHSI that enables fast, site-specific bioconjugation without copper catalysis; CriPec®, a polymeric nanoparticle platform that transforms drug molecules into nanoparticles with negligible protein corona formation, enabling enhanced tumour accumulation and sustained drug release (clinically demonstrated at approximately 4-fold higher tumour uptake versus conventional docetaxel); and CriVac®, a vaccine platform that combines CriPec® nanoparticles with CliCr® conjugation to produce virus-mimicking coated nanoparticles that induce immune responses against displayed antigens. Its lead clinical asset, CPC634 (CriPec®-docetaxel), is in Phase 2 development for platinum-resistant ovarian cancer and other solid tumours, supported by a €2.5 million Horizon 2020 SME Instrument grant.

The company operates a licensing- and partnership-led business model rather than a commercial product sales model. Revenue is generated through technology licensing agreements (both exclusive and non-exclusive) for the CliCr®, CriPec®, and CriVac® platforms with pharmaceutical and biotech partners, supplemented by research and distribution arrangements. CliCr® reagents for non-GMP research are sold through Iris Biotech GmbH as authorized distributor; GMP applications and clinical-stage engagements are handled directly via the business development team. Strategic partners include Lonza (CliCr® embedded in its Bioconjugation Toolbox), Curapath (co-exclusive license for nucleic acid drug delivery), Sapreme Technologies (non-exclusive license), TBD Pharmatech (exclusive supply), Intravacc (COVID-19 vaccine collaboration), and iTeos Therapeutics (immuno-oncology). To date the company has raised over €20 million in equity financing from Thuja Capital, BioGeneration Ventures, Chemelot Ventures, Aglaia BioMedical Ventures, DROIA Oncology Ventures, and regional Dutch/Belgian funds, complemented by European Commission grants.

The company is small (1–10 employees) and is led by CEO/CMO Dr. Axel Mescheder (appointed November 2018, formerly of Pfizer, MSD, MediGene, and TopoTarget), Founder/CSO Dr. Cristianne Rijcken, CFO Andre Verwei (appointed 2019), CBO Jeroen Tonnaer, and Board Chairman Dr. Werner Cautreels (former CEO of Selecta Biosciences). The current strategic emphasis, evidenced by a cluster of 2023–2025 CliCr®-focused partnerships, has shifted from internal clinical development of CPC634 toward broader out-licensing of the CliCr® platform into bioconjugation, peptide synthesis, nucleic acid delivery, and gene-editing applications.

Cristal Therapeutics firmographics

Firmographics
Name
Cristal Therapeutics
Legal name
Cristal Therapeutics
Website
https://cristaltherapeutics.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Cristal Therapeutics is a Dutch clinical-stage biotech that develops and licenses three proprietary platforms — CliCr® copper-free click chemistry, CriPec® polymeric nanomedicines, and CriVac® vaccines — serving pharmaceutical and biotech partners developing cancer therapeutics, bioconjugates, and gene-editing delivery systems.
Ownership category
akta.pro rank

Where Cristal Therapeutics is headquartered

Location

Headquarters

HQ city
Maastricht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Cristal Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Technology Licensing: Cristal Therapeutics licenses its proprietary technology platforms (CliCr, CriPec, CriVac) to pharmaceutical and biotech partners under license agreements for various diagnostic and therapeutic applications. The company offers both exclusive and non-exclusive licensing arrangements.
  2. Research Grants: The company has secured significant grant funding from European programs including Horizon 2020 SME Instrument grants (€2.5 million) and INNOSUP grants to support clinical development and platform advancement.
  3. Equity Financing: Private company that has raised over €20M in equity financing from venture capital investors including Thuja Capital, BioGeneration Ventures, Aglaia BioMedical Ventures, DROIA Oncology Ventures, and others.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Cristal Therapeutics product offering

Product offering

Core offering

Cristal Therapeutics develops and licenses proprietary nanomedicine platforms for therapeutic and diagnostic applications. The company offers three interconnected technology platforms — CliCr® (copper-free click chemistry reagents), CriPec® (polymeric nanoparticle drug delivery), and CriVac® (vaccine technology) — licensed to pharmaceutical and biotech partners. Its lead clinical candidate CPC634 combines CriPec® nanoparticles with docetaxel and is in Phase 2 development for platinum-resistant ovarian cancer.

Product overview

Cristal Therapeutics is a clinical-stage pharmaceutical company offering three interconnected proprietary technology platforms: CliCr® (copper-free click chemistry reagent), CriPec® (polymeric nanoparticle drug delivery platform), and CriVac® (vaccine technology platform). These platforms work together to improve therapeutic profiles through superior conjugation (CliCr®), enhanced target specificity (CriPec®), and selective immune responses (CriVac®). The lead product candidate CPC634 combines CriPec® nanoparticles with docetaxel for cancer treatment. The company licenses these technologies under various agreement types and also commercializes CliCr® reagents through distribution partners.

Differentiator

Problem solved

Functional benefit

Brands

  • CliCr®: Proprietary copper-free click chemistry reagent technology platform enabling efficient, site-specific and stable conjugation of biomolecules for therapeutic and diagnostic applications.
  • CriPec®
  • CriVac®
  • CPC634

Products and services

  • CliCr® Copper-Free Click Chemistry Reagent Proprietary copper-free click chemistry reagent platform based on TMTHSI (tetramethyl tetrahydroisoquinoline) that enables site-specific, stable, and fast conjugation of small molecules, biologics, nanoparticles, and other moieties via strain-promoted azide-alkyne cycloaddition, licensed to partners for therapeutic and diagnostic applications.
  • CriPec® Polymeric Nanoparticle Drug Delivery Platform Polymeric nanoparticle technology platform that transforms drug molecules into customized nanoparticles via self-assembly, providing enhanced tumor accumulation, negligible protein corona formation, sustained drug release at target sites, and improved therapeutic profiles for cancer and other diseases, licensed to pharmaceutical partners.
  • CriVac® Vaccine Technology Platform Proprietary vaccine technology platform combining biodegradable CriPec® nanoparticles with CliCr® conjugation chemistry for fast and controlled antigen conjugation, generating virus-mimicking coated nanoparticles that induce potent immune responses safely against displayed antigens, applicable for vaccine development.
  • CPC634 (CriPec®-Docetaxel) Lead clinical-stage nanomedicine candidate combining CriPec® nanoparticles with entrapped docetaxel (Taxotere®) for treatment of platinum-resistant ovarian cancer and solid tumors, designed to enable enhanced tumor accumulation and localized drug release.

Quantifiable outcome

  • 4-fold higher tumour accumulation of CriPec-docetaxel compared to conventional Taxotere in clinical studies
  • +4 more outcomes

Companies that use Cristal Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Cristal Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cristal Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • CurapathcoreOEM/ Whitelabel/ Licensing Partner · 26 November 2025Co-exclusive license agreement for CliCr bioconjugation platform. Curapath serves as exclusive CDMO to apply CliCr for delivery of nucleic acids via targeted polymeric and lipid nanoparticles (LNPs). Both parties have right to grant sublicenses in nucleic acid drug delivery field.
  • TBD PharmatechcoreImplementation/ SI/ Consulting Partner · 23 September 2025Exclusive supply agreement where TBD Pharmatech serves as sole supplier of CliR conjugation reagents. Partnership leverages TBD Pharmatech's GMP manufacturing expertise and quality assurance for reliable, scalable production of CliCr to support Cristal Therapeutics' initiatives.
  • Sapreme TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 11 September 2025Non-exclusive license agreement allowing Sapreme Technologies to leverage CliCr platform in development of next-generation therapeutics based on their endosomal escape technology. Integration with CliCr enables accelerated pipeline development with robust manufacturing strategy.
  • Iris Biotech GmbHcoreChannel Partner/ Reseller/ Distributor · 25 January 2023Iris Biotech sells CliCr and CliCr reagents for non-GMP research purposes as authorized distributor. For GMP applications, customers connect directly with Cristal Therapeutics.
  • LonzacoreStrategic or Co-development Partner · 17 January 2023Cristal Therapeutics collaborates with Lonza on CliCr technology. CliCr is offered as part of Lonza's Bioconjugation Toolbox and Early Development Service offering. Lonza supports the entire product lifecycle from drug discovery through commercial manufacturing. The collaboration extends the impact of CliCr for use in bioconjugation applications in therapeutic and diagnostic products.
  • IntravacccoreStrategic or Co-development Partner · 6 January 2021Strategic collaboration to develop novel vaccine programs against human diseases with initial focus on COVID-19. Cristal provides CliCr and CriVac technology; Intravacc provides OMV technology and detoxified LPS technology. First joint CriVac vaccine candidate targets receptor-binding domain of SARS-CoV-2.
  • iTeos TherapeuticscoreStrategic or Co-development Partner · 6 December 2016Strategic partnership for development of immuno-oncology therapeutic candidates using CriPec nanotech platform. Initial goal to determine efficacy of iTeos immuno-oncology drug candidates in preclinical models. Option for iTeos to license Cristal's platform for up to three immune tumor-targeting programs.
  • PX BiosolutionsminorStrategic or Co-development Partner · 14 July 2015Collaboration focused on application of CriVac vaccine technology for design of innovative vaccines. PX Biosolutions' DCtag vaccine formulations combined with Cristal's CriVac technology for enhanced vaccine platform flexibility.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Cristal Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cartesian Therapeutics (formerly Selecta Biosciences): Clinical-stage biotech developing nanoparticle-based immunomodulatory therapies (ImmTOR, Treg therapies). Directly comparable as a nanoparticle platform company with both therapeutics and vaccine applications, overlapping with both CriPec and CriVac.
  • Heidelberg Pharma: German biotech developing antibody-drug conjugates based on proprietary amanitin payload and linker chemistry. Directly comparable as a bioconjugation platform company with a similar licensing-focused business model overlapping with CliCr chemistry applications.
  • NBE Therapeutics: Swiss biotech (now part of Boehringer Ingelheim) that developed site-specific antibody-drug conjugates using enzymatic conjugation chemistry. Directly comparable to Cristal as a bioconjugation platform company targeting ADCs and related modalities.
  • Starpharma: Australian-listed biotech developing dendrimer-based nanoparticle drug delivery (DEP platform) with applications in oncology and infectious disease. Direct peer as a clinical-stage nanomedicine platform company with both internal products and licensing deals.
  • NanoCarrier: Japanese clinical-stage biotech developing polymeric micelle nanoparticle drug delivery systems (e.g., NC-6004, NC-6300) for oncology. Direct peer in the polymeric nanoparticle drug delivery space, comparable in stage, mechanism, and oncology focus to CriPec.
  • Vivesto (formerly Oasmia Pharmaceutical): Swedish nanomedicine company developing proprietary nanoparticle formulations of chemotherapeutics (e.g., Apealea/paclitaxel). Direct peer as a nanoparticle reformulation company targeting oncology indications with improved tolerability profiles.
  • CytImmune Sciences: Clinical-stage biotech developing tumor-targeted gold nanoparticle therapeutics (Aurimune, CYT-6091) combining delivery and immunotherapy. Direct peer in oncology-focused nanoparticle drug delivery and a comparable platform-based licensing model.
  • Arcturus Therapeutics: Clinical-stage biotech developing lipid nanoparticle (LNP)-enabled RNA medicines, including partnered COVID-19 and influenza vaccines. Directly comparable as an LNP delivery platform company with applications in both therapeutics and vaccines, overlapping with CriPec and CriVac.

Emerging players

  • Sapreme Technologies: Dutch preclinical biotech developing endosomal escape technology to enhance intracellular delivery of therapeutics (ADCs, oligonucleotides). Comparable as a recently-signed CliCr licensee and a delivery-technology peer adjacent to CliCr-enabled bioconjugation.
  • Curapath: Spanish CDMO specializing in polymer and lipid-based drug delivery systems (LNPs, polymeric nanoparticles). Co-exclusive CliCr licensee for nucleic acid delivery via LNPs; comparable as an emerging delivery-tech peer adjacent to both CliCr and CriPec applications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cristal Therapeutics social profiles

Digital presence

Cristal Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cristal Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Cristal Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cristal Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cristal Therapeutics

What does Cristal Therapeutics do?

Cristal Therapeutics develops and licenses proprietary nanomedicine platforms for therapeutic and diagnostic applications. The company offers three interconnected technology platforms — CliCr® (copper-free click chemistry reagents), CriPec® (polymeric nanoparticle drug delivery), and CriVac® (vaccine technology) — licensed to pharmaceutical and biotech partners. Its lead clinical candidate CPC634 combines CriPec® nanoparticles with docetaxel and is in Phase 2 development for platinum-resistant ovarian cancer.

Is Cristal Therapeutics a public or private company?

Cristal Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cristal Therapeutics founded?

Cristal Therapeutics was founded in 2011. It employs 1 to 10 people.

Where is Cristal Therapeutics based?

Cristal Therapeutics is headquartered in Maastricht, Netherlands, in the Europe region.

How does Cristal Therapeutics make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are research Grants and equity Financing.

Who are Cristal Therapeutics's main competitors?

Direct peers on record are Cartesian Therapeutics (formerly Selecta Biosciences), Heidelberg Pharma, NBE Therapeutics, Starpharma, NanoCarrier, Vivesto (formerly Oasmia Pharmaceutical), CytImmune Sciences and Arcturus Therapeutics. Emerging players are Sapreme Technologies and Curapath.

Does Cristal Therapeutics have an API?

No public API is recorded for Cristal Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CurapathCurapath and Cristal Therapeutics Partner to Advance Next-Generation Targeted Drug Delivery with CliCr® Bioconjugation TechnologyCurapath and Cristal Therapeutics have entered into a co-exclusive license agreement to integrate Cristal's CliCr® bioconjugation technology into Curapath's drug delivery systems. Under this partnership, Curapath serves as the exclusive CDMO authorized to use the CliCr® platform for targeted nucleic acid delivery via polymer and lipid nanoparticles. This collaboration aims to enhance the precision and scalability of next-generation therapeutics targeting extrahepatic tissues.CristaltherapeuticsCristal Therapeutics and TBD Pharmatech enter exclusive supply agreement for CliCr® conjugation reagentsCristal Therapeutics has entered an exclusive supply agreement with TBD Pharmatech, designating the latter as the sole supplier of its CliCr® conjugation reagents. This partnership secures Cristal's supply chain for its bioconjugation platform, leveraging TBD Pharmatech's GMP manufacturing capabilities to support current and future drug development initiatives. The financial terms of the agreement were not disclosed.CristaltherapeuticsCristal TherapeuticsCristal Therapeutics describes its CliCr technology platform, a proprietary click chemistry platform for generating conjugate products such as bioconjugate-based therapeutics, nanomedicines, biomaterials and diagnostics. The platform is available for testing through joint proof of concept studies, with further development under license, and is offered in partnership with Lonza as part of the Lonza Bioconjugation Toolbox and Early Development Service.PR NewswireSynaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology OfferingSynaffix signed a licensing agreement with Cristal Therapeutics to obtain exclusive rights to CliCr metal-free click chemistry for its ADC platform. The deal expands the GlycoConnect tool kit, enhancing payload versatility and supporting gene therapy and immune cell engager applications.PR NewswireSynaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology OfferingSynaffix B.V. signed a licensing agreement with Cristal Therapeutics to obtain exclusive rights to the CliCr® metal-free click chemistry technology. The deal expands Synaffix's GlycoConnect™ ADC tool kit, enhancing versatility across cytotoxic payloads and supporting expansion into antibody-based targeted gene therapy and immune cell engager applications. Cristal Therapeutics views this as an important milestone in executing its strategy to commercialize CliCr® in different fields of therapeutic bioconjugates.PR NewswireCristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine PlatformsIntravacc and Cristal Therapeutics announced a strategic collaboration to develop novel vaccine programs, with an initial focus on generating a COVID-19 vaccine candidate using Cristal's CriVac® platform based on CriPec® nanoparticles and CliCr® conjugation technology. Under the agreement, Intravacc will provide access to its proprietary outer membrane vesicles (OMV) technology and detoxified LPS technology to enhance immune activation. The companies will jointly explore next steps after completing the preclinical evaluation period to advance the program against a broad range of human diseases.PR NewswireCristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biolCristal Therapeutics announced publication of research in Chemical Science journal on its CliCr® technology platform, featuring TMTHSI as a superior copper-free click reagent for conjugating small molecules, biologics, and nanoparticles. The platform enables the company's proprietary CriPec® nanomedicines and CriVac® vaccine product development while also being available for licensing as stand-alone technology. The company is actively seeking partners for various applications of the CliCr® technology.NatureA clinical-phase cancer biotech with nanomedicine partnering opportunitiesCristal Therapeutics, a clinical-phase cancer biotech, is seeking partners for its nanomedicine platform CriPec, which encapsulates docetaxel to improve efficacy and safety. Its lead asset CPC634 is in phase 2 for platinum-resistant ovarian cancer, with plans to expand into gastric, prostate, and breast cancers. The company aims to find a partner for late-phase development and registration.NatureA clinical-phase cancer biotech with nanomedicine partnering opportunitiesCristal Therapeutics, a clinical-phase cancer biotech, is seeking partnering opportunities for its CriPec nanomedicine platform. Its lead asset CPC634, an encapsulated docetaxel, is in phase 2 for platinum-resistant ovarian cancer, with plans to expand into gastric, prostate, and breast cancers. The company aims to partner with large pharma or biotech for late-phase development and registration.Brightlands Venture PartnersCristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancerCristal Therapeutics, a Maastricht-based nanomedicine developer, closed a €12.8 million financing round on January 19, 2017 led by Dutch investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures, with BOM, LIOF and LBDF participating. The funds will cover a phase Ib trial of its lead candidate CriPec docetaxel, a phase IIa trial later this year, and preclinical work on CriPec DUO and oligonucleotide programs through 2019.